{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:36Z","timestamp":1790806836491,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.oret.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T19:32:38Z","timestamp":1739388758000},"page":"807-811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7002-4620","authenticated-orcid":false,"given":"Thomas W.","family":"Hejkal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-2802","authenticated-orcid":false,"given":"Shruti","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pukhraj","family":"Rishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6088-5280","authenticated-orcid":false,"given":"Samiksha F.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2911-1022","authenticated-orcid":false,"given":"Paul J.","family":"Rychwalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.02.009_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.02.009_bib2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bjo.2008.141481","article-title":"Anti-vascular endothelial growth factor and retinopathy of prematurity","volume":"92","author":"Sears","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.009_bib3","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment \u2013 a review","volume":"100","author":"H\u00e5rd","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.oret.2025.02.009_bib4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.oret.2025.02.009_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis","volume":"41","author":"Kaushal","year":"2021","journal-title":"J Perinatol"},{"key":"10.1016\/j.oret.2025.02.009_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis","volume":"4","author":"Haigh","year":"2008","journal-title":"Organogenesis"},{"key":"10.1016\/j.oret.2025.02.009_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.009_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11845-017-1684-y","article-title":"Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity","volume":"187","author":"\u015eahin","year":"2018","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.oret.2025.02.009_bib9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.009_bib10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.009_bib11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaapos.2016.09.012","article-title":"A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity","volume":"20","author":"Khodabande","year":"2016","journal-title":"J AAPOS"},{"key":"10.1016\/j.oret.2025.02.009_bib12","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/aos.13004","article-title":"Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison","volume":"96","author":"Han","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.009_bib14","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.02.009_bib15","article-title":"Risk factors for persistent avascular retina following bevacizumab therapy for retinopathy of prematurity","volume":"63","author":"Robles-Holmes","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.02.009_bib16","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes","volume":"129","author":"Freedman","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.02.009_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1203068","article-title":"Incomplete peripheral retinal vascularisation in retinopathy of prematurity: is it the consequence of changing oxygen saturation?","volume":"11","author":"Yehiam","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.oret.2025.02.009_bib18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamaophthalmol.2021.3192","article-title":"Choice of dose level for a randomized clinical trial of low-dose bevacizumab vs laser for type 1 retinopathy of prematurity","volume":"139","author":"Kraker","year":"2021","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:06:13Z","timestamp":1754035573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2468653025000612"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.02.009","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Bevacizumab 0.03 mg for Treatment of Type 1 Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}